Celerion and Korean Drug Development Fund Form Collaboration to Strengthen Early Phase Clinical Research in South Korea
Celerion and the Korean Drug Development Fund announced a formal collaboration
Celerion and the Korean Drug Development Fund (KDDF) announced a formal collaboration to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea.
The agreement in the form of a Memorandum of Understanding (MOU) provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion’s extensive experience and expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites. The collaboration will support a sharing of knowledge between KDDF and Celerion, and will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market. The MOU further enhances both organizations’ ability to effectively apply principles of translational medicine to the development of innovative new drugs.
“We are delighted to collaborate with KDDF, and provide early clinical research expertise to support and strengthen the emerging pharmaceutical industry in South Korea,” saidSusan Thornton PhD, President and CEO of Celerion. “Our agreement with KDDF is further evidence of Celerion’s enthusiasm and commitment to contributing to the growth of South Korea’s biomedical research industry.”
“The KDDF is very happy to have established a partnership with Celerion. This collaboration is aligned to our vision to build effective partnerships between government, industry and academia,” said Dongho Lee MD MBA, CEO of KDDF. “Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation.”
Celerion will support all programs with KDDF, from the recently announced business expansion within the Biomedical Research Institute at Seoul National University Hospital (SNUH), in South Korea.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
